42 results on '"Dussart C"'
Search Results
2. Quel est le parcours de santé des patients ayant présenté une infection invasive à méningocoque ? (Etude EXPRIIM)
3. Le rôle du pharmacien en officine et en pharmacie hospitalière dans la prévention en santé publique en France
4. HTA74 Could Artificial Intelligence Support Prediction of Reimbursement Decisions in Scotland? A Pilot Project
5. Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks
6. POSB263 Analysis of the Influence of Implicit Factors on the HTA Deliberative Process: Results of a Survey in 5 European Countries
7. Utilisation des TROD et autotests : enquête auprès des pharmaciens officinaux de la région Auvergne–Rhône-Alpes
8. Étude de l’impact économique des cônes en métal poreux dans les arthroplasties totales du genou
9. Évaluation du service rendu d’un centre d’information pharmaceutique sur la prise en charge des patients
10. PMU9 HIGH DRUG PRICES AND THE ADEQUACY OF RETURN ON PUBLIC INVESTMENT INTO DRUG RESEARCH AND DEVELOPMENT BY THE U.S. NATIONAL INSTITUTES OF HEALTH (NIH).
11. PND108 QUALITY OF LIFE OF PATIENTS AFTER ISCHAEMIC STROKE TREATED IN A PROVINCIAL HOSPITAL IN POLAND
12. PMH8 PSYCHOLOGICAL ASPECTS OF GENETIC COUNSELING IN RARE GENETIC CNS DISORDERS - SHOULD REGULATORS BE MORE INVOLVED?
13. P119 Intravenous antibiotic prescriptions after phone consultation for cystic fibrosis patients
14. PHP125 - COHORT TEMPORARY AUTHORISATION FOR USE IN FRANCE, FRENCH EXPERIENCE OF EARLY-ENTRY PROGRAM 2014-2018
15. PHP118 - IMPACT OF COHORT TEMPORARY AUTHORISATION FOR USE ON PRICE IN FRANCE
16. PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?
17. PSY45 - BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE
18. PSY159 - COMPARISON OF ORPHAN DRUG PRICES: BELGIUM VS LUXEMBOURG
19. PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIES
20. PSY150 - INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE
21. Orphan Drugs Versus Ultra-Orphan Drugs: Price Comparison in England
22. Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals
23. Assessment of Hta and Price Heterogeneity of Oncology Products: A Comparison Between France and Germany
24. Rates of Patient-Reported Outcome Claims for Orphan Drugs Approved by the European Medicines Agency
25. Hta Outcomes for Orphan Drugs in Oncology: Comparison of France, Germany and England
26. Non-Profit Drug Research and Development at a Crossroads: The Case Study of Genethon
27. Does Disease Area Have An Impact on Orphan Drug Prices?
28. Funding breakthrough therapies: A systematic review and recommendation
29. Potential Funding Sources For Breakthrough Therapies
30. Could Healthcoin Be A Revolution In Healthcare?
31. Current trends in vasopressor use to the operating room: A pharmacoepidemiologic study in French teaching and military hospitals
32. L’évaluation médico-économique des stratégies thérapeutiques en milieu hospitalier : une revue systématique des travaux français
33. Étude de l’usage du fer injectable en établissement de santé et de son impact en terme d’économie hospitalière
34. Impact du sugammadex sur les consommations de curares : étude pharmaco-épidémiologique multicentrique dans les centres hospitalo-universitaires et hôpitaux d’instructions des armées français
35. Qualité optique après phacoémulsification par mini-incision de 2,2mm associée à une I/A bimanuelle, à propos de 154 yeux
36. Statistical study of the critical pitting temperature of 22-05 duplex stainless steel
37. Neuropathic complications after 157 procedures of continuous popliteal nerve block for hallux valgus surgery. A retrospective study
38. Complications neuropathiques après 157 procédures de blocs continus du nerf sciatique au creux poplité pour cure d’hallux valgus. Étude rétrospective
39. Natural variability and response interpretation of fecundity, vertebrate-like sex-steroid levels and energy status in the New Zealand mudsnail Potamopyrgus antipodarum (Gray)
40. Arrêt de la valorisation humanitaire des médicaments non utilisés : enjeux et perspectives
41. Optimisation des procédures de manipulation des chimiothérapies anticancéreuses: impact des contrôles de contamination environnementaux
42. Mycoses d'importation: le point sur la paracoccidioïdomycose
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.